Development of novel bio-therapy using hybrid peptide against intrahepatic cholangiocarcinoma

点击翻译按钮获取中文摘要

It is known that the interleukin-4 receptor alpha (IL-4R alpha) is highly expressed on the surface of various human solid tumors. We have newly designed IL-4R alpha-lytic hybrid peptide composed of binding peptide to IL-4R alpha and cell-lytic peptide. Here, we evaluated the antitumor activity of the IL-4R alpha-lytic hybrid peptide as a novel molecular targeted therapy in human biliary tract cancer (BTC) cells. IL-4R alpha-lytic hybrid peptide showed cytotoxic activity in siz BTC cell lines with a concentration that killed 50% of all cells (IC50) as low as 5 micromoles/L. In addition, intravenous administration of IL-4R alpha-lytic hybrid peptide significantly inhibited tumor growth in a xenograft model of human BTC in vivo. Taken together, these results indicated that the IL-4R alpha-lytic hybrid peptide is a potent agent that might provide a novel therapy for patients with BTC.